Gland Pharma Limited Total Liabilities
Gland Pharma Limited total liabilities. Based on the latest financial reports, Gland Pharma Limited (GLAND) has total liabilities worth Rs-103.58 Billion INR (≈ $-1.12 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Gland Pharma Limited's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Gland Pharma Limited (2017–2026)
Total liabilities of Gland Pharma Limited from 2017 to 2026. This chart illustrates how Gland Pharma Limited's total liabilities have evolved over time, based on quarterly financial data.
Gland Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Gland Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Promotora y Operadora de Infraestructura S. A. B. de C. V
MX:PINFRA
|
Mexico | MX$16.70 Billion |
|
Shenzhen Kaifa Technology Co Ltd
SHE:000021
|
China | CN¥11.86 Billion |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
USA | $3.05 Billion |
|
Nestle (Malaysia) Bhd
KLSE:4707
|
Malaysia | RM2.81 Billion |
|
Cirrus Logic Inc
NASDAQ:CRUS
|
USA | $371.15 Million |
|
Ultrapar Participações S.A
F:UGR
|
Germany | €31.62 Billion |
|
Varonis Systems
NASDAQ:VRNS
|
USA | $1.21 Billion |
|
Herc Holdings Inc
NYSE:HRI
|
USA | $11.83 Billion |
Liability Composition Analysis (2017–2026)
This chart breaks down Gland Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Gland Pharma Limited.
Liquidity & Leverage Metrics
Gland Pharma Limited Total Liabilities Ratios Explained
Gland Pharma Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gland Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gland Pharma Limited (2017–2026)
The table below shows the annual total liabilities of Gland Pharma Limited from 2017 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs21.53 Billion ≈ $232.83 Million |
+3.80% |
| 2025-03-31 | Rs20.74 Billion ≈ $224.31 Million |
+7.06% |
| 2024-03-31 | Rs19.37 Billion ≈ $209.52 Million |
+136.61% |
| 2023-03-31 | Rs8.19 Billion ≈ $88.55 Million |
+21.13% |
| 2022-03-31 | Rs6.76 Billion ≈ $73.11 Million |
+14.03% |
| 2021-03-31 | Rs5.93 Billion ≈ $64.11 Million |
+34.80% |
| 2020-03-31 | Rs4.40 Billion ≈ $47.56 Million |
-33.52% |
| 2019-03-31 | Rs6.62 Billion ≈ $71.54 Million |
+27.44% |
| 2018-03-31 | Rs5.19 Billion ≈ $56.14 Million |
+35.21% |
| 2017-03-31 | Rs3.84 Billion ≈ $41.52 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The … Read more